November 12 from 10:30 am – 11:15 pm PST
Supported By: UCB,Inc.
This is a promotional program sponsored by UCB. This session will explore the reasons why non-radiographic axial spondyloarthritis (nr-axspa) is underdiagnosed and underrecognized in the United States. The session will then provide recommendations for MRI implementation and interpretation for nr-axspa, leveraging a hypothetical patient case to complement the educational information. Lastly, the session will describe clinical trial outcomes in support of cimzia® (certolizumab pegol)—the first and only FDA approved tnf inhibitor indicated for the treatment of adults with active nr-axspa with objective signs of inflammation.